Application of cucurbitacine B in preparation of medicine for preventing and treating inflammatory bowel disease

By using cucurbitacin B to prepare various drug formulations, the problems of limited efficacy and large side effects of existing IBD treatment drugs have been solved, providing a low-toxicity and highly effective treatment plan for inflammatory bowel disease.

CN118976031APending Publication Date: 2024-11-19THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410903966.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-08
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing IBD treatments have problems such as limited efficacy, high relapse rate, high cost, and significant side effects. In particular, there is a lack of effective and low-toxicity treatment options for patients who do not respond well to glucocorticoids or immunosuppressants.

Method used

Cucurbitacin B is used as the active ingredient to prepare various drug dosage forms such as granules and ordinary tablets for the prevention and treatment of inflammatory bowel disease.

Benefits of technology

Cucurbitacin B significantly inhibited weight loss in UC mice, improved DAI scores, reduced colonic shortening, and provided a low-toxicity, highly effective treatment for inflammatory bowel disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976031A_ABST
    Figure CN118976031A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicines for treating inflammatory bowel diseases, and discloses application of cucurbitacine B in preparation of medicines for preventing and treating inflammatory bowel diseases. Cucurbitacine B is a tetracyclic triterpenoid compound naturally existing in cucurbitaceae plants and widely exists in plants such as cucumbers, watermelons and pumpkins. Currently, cucurbitacine B is mainly used for developing drugs for resisting cancers, viruses and the like. Researches find that cucurbitacin B can significantly inhibit weight loss of UC mice, significantly improve DAI scores of the UC mice and significantly reduce the colon shortening degree of the UC mice, and application of cucurbitacin B in prevention and treatment of inflammatory bowel diseases is provided. According to the invention, the effect of cucurbitacine B in preventing and treating inflammatory bowel diseases is found for the first time, and cucurbitacine B is expected to become a low-toxicity and high-efficiency medicine and is applied to preventing and treating inflammatory bowel diseases of human bodies.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of inflammatory bowel disease medicine, and in particular to application of cucurbitacin B in preparing medicines for preventing and treating inflammatory bowel disease. Background Art

[0002] Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a type of intestinal inflammatory disease with unclear etiology and pathogenesis. In recent years, it is generally believed that it may be related to environmental factors, genetic susceptibility, immune abnormalities, and changes in intestinal microorganisms. Due to the gradual increase in incidence, IBD has become a common digestive system disease.

[0003] Existing clinical treatment drugs for IBD are mainly divided into two categories: non-biological agents and biologics. Non-biological agents include glucocorticoids, immunomodulators, and aminosalicylic acids. These drugs have short half-lives, low production costs, and high patient dependence for oral administration. They can improve clinical symptoms but still have problems such as limited efficacy, high recurrence rate, and long treatment cycle. Biologics include monoclonal antibodies, recombinant cytokines, and specific antagonists of receptors and cytokines. Biologics are a good treatment option for patients who respond poorly or have no response to small molecule drugs such as glucocorticoids or immunosuppressants, and for patients who have serious adverse reactions to other therapeutic drugs. But in addition to potential side effects and response variability, the high cost of biologics also brings a burden to patients with financial difficulties.

[0004] Cucurbitacin B (CuB) is a tetracyclic triterpenoid compound naturally found in Cucurbitaceae plants. It is known for its bitter taste and multiple biological activities and is widely found in plants such as cucumber, watermelon, and pumpkin. Cucurbitacin B has multiple pharmacological effects, especially showing significant potential in anti-cancer and anti-viral effects.

[0005] Natural products have the advantages of less toxic side effects, low cost, multiple targets, and multiple pathways, and have great clinical application prospects. At present, finding cheaper, less toxic, highly effective, and orally administrable natural medicines for the treatment of inflammatory bowel disease still has important clinical value. Summary of the invention

[0006] In order to solve the above-mentioned technical problems in the treatment of inflammatory bowel disease, the present invention provides the use of cucurbitacin B in the preparation of a drug for preventing or treating inflammatory bowel disease. The present invention has found through research that cucurbitacin B can significantly inhibit the weight loss of UC mice, significantly improve the DAI score of UC mice, and significantly reduce the degree of shortening of the colon of UC mice, and provides the use of cucurbitacin B in the prevention and treatment of inflammatory bowel disease.

[0007] The specific technical scheme of the present invention is: In a first aspect, the present invention provides the use of cucurbitacin B in the preparation of a medicament for preventing and / or treating inflammatory bowel disease.

[0008] The present invention has found through research that cucurbitacin B can significantly inhibit the weight loss of UC mice, significantly improve the DAI score of UC mice, and significantly reduce the shortening degree of the colon of UC mice, and provides the application of cucurbitacin B in the prevention and treatment of inflammatory bowel disease. Cucurbitacin B is a tetracyclic triterpenoid compound naturally present in Cucurbitaceae plants, and is widely present in plants such as cucumbers, watermelons, and pumpkins. At present, cucurbitacin B is mainly used in the development of anti-cancer, antiviral and other drugs. The present invention is the first to discover the role of cucurbitacin B in the prevention and treatment of inflammatory bowel disease. Cucurbitacin B is expected to become a low-toxic, high-efficiency drug used in the prevention and treatment of inflammatory bowel disease in humans.

[0009] As a preferred embodiment of the above technical solution, the dosage form of the drug includes granules, ordinary tablets, dispersible tablets, effervescent tablets, orally disintegrating tablets, lozenges, chewable tablets, capsules, soft capsules, microcapsules, pills, powders, pellets, sustained-release preparations, controlled-release preparations, oral liquid preparations and injections.

[0010] Based on the above application of cucurbitacin B in the prevention and treatment of inflammatory bowel disease given in the present invention, cucurbitacin B is used as an active ingredient by conventional pharmaceutical means, and one or more pharmaceutically acceptable excipients are added to cucurbitacin B to prepare it into a pharmaceutical preparation such as granules, ordinary tablets, dispersible tablets, etc. The pharmaceutical preparation thus obtained can be used in the prevention and treatment of inflammatory bowel disease in the human body.

[0011] In a second aspect, the present invention provides the use of cucurbitacin B in the preparation of a medicament for preventing and / or treating ulcerative colitis.

[0012] Further preferably, the dosage form of the drug includes granules, ordinary tablets, dispersible tablets, effervescent tablets, orally disintegrating tablets, lozenges, chewable tablets, capsules, soft capsules, microcapsules, pills, powders, pellets, sustained-release preparations, controlled-release preparations, oral liquid preparations and injections.

[0013] In a third aspect, the present invention provides a composition for treating inflammatory bowel disease, wherein the active ingredient of the composition is cucurbitacin B.

[0014] More preferably, the inflammatory bowel disease is ulcerative colitis.

[0015] Preferably, the composition comprises one or more pharmaceutically acceptable excipients.

[0016] Preferably, the composition is prepared into granules, ordinary tablets, dispersible tablets, effervescent tablets, orally disintegrating tablets, lozenges, chewable tablets, capsules, soft capsules, microcapsules, pills, powders, pellets, sustained-release preparations, controlled-release preparations, oral liquid preparations and injections.

[0017] Compared with the prior art, the present invention has the following technical effects: (1) The present invention has found through research that cucurbitacin B can significantly inhibit the weight loss of UC mice, significantly improve the DAI score of UC mice, and significantly reduce the degree of colon shortening of UC mice, thus providing the application of cucurbitacin B in the prevention and treatment of inflammatory bowel disease.

[0018] (2) The present invention can provide more low-toxic and highly effective drugs for the treatment of inflammatory bowel disease. Through research, the present invention found that cucurbitacin B can significantly inhibit the weight loss of UC mice, significantly improve the DAI score of UC mice, and significantly reduce the degree of colon shortening of UC mice, and provides the application of cucurbitacin B in the prevention and treatment of inflammatory bowel disease. Cucurbitacin B is a tetracyclic triterpenoid compound naturally present in Cucurbitaceae plants, and is widely found in plants such as cucumbers, watermelons, and pumpkins. At present, cucurbitacin B is mainly used in the development of anti-cancer, antiviral and other drugs. The present invention is the first to discover the role of cucurbitacin B in the prevention and treatment of inflammatory bowel disease. Cucurbitacin B is expected to become a low-toxic and highly effective drug for use in the prevention and treatment of inflammatory bowel disease in humans. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 The results of the effects of cucurbitacin B on DSS-induced UC mice in Example 1; Figure 2 These are the results of the effect of cucurbitacin B in Example 2 on colon pathology in DSS-induced UC mice. DETAILED DESCRIPTION

[0020] The present invention will be further described below in conjunction with embodiments. Those of ordinary skill in the art will be able to implement the present invention based on these descriptions. In addition, the embodiments of the present invention involved in the following description are generally only embodiments of a part of the present invention, rather than all embodiments. Therefore, based on the embodiments in the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative work should belong to the scope of protection of the present invention.

[0021] Example 1 In this example, cucurbitacin B was administered to DSS-induced UC mice, and the weight changes, disease activity index (DAI) scores, and spleen coefficients of the UC mice were tracked. The steps were as follows: Thirty (20 ± 2 g) male C57BL / 6 SPF mice were randomly divided into five groups (6 mice in each group) and treated as follows: Control group (referred to as Control group): blank control, without any treatment; Model group (denoted as Model group): positive control, free drinking of 3% DSS solution (mass fraction, the same below) for 7 days to induce UC; SASP group: The mice were allowed to drink 3% DSS solution freely for 7 days to induce UC, and SASP drug was administered intragastrically at a dose of 400 mg / kg per day, divided into 2 doses, for 7 consecutive days; The low-dose cucurbitacin B group (referred to as the cucurbitacin B 1 mg / kg group) was given free drinking of 3% DSS solution for 7 days to induce UC, and cucurbitacin B was administered orally at a dose of 2 mg / kg daily, divided into 2 doses (1 mg / kg each time), for 7 consecutive days. The high-dose cucurbitacin B group (denoted as cucurbitacin B 2 mg / kg group) was allowed to freely drink 3% DSS solution for 7 days to induce UC, and cucurbitacin B was gavaged at a dose of 4 mg / kg daily, divided into 2 gavages (2 mg / kg each time), for 7 consecutive days.

[0022] The weight, stool and other abnormal conditions of mice were recorded daily in each group, and the disease activity index (DAI) score was obtained in a blind manner. The mice were killed on the 8th day and cervical dislocation was performed for anatomical sampling. Figure 1 , Figure 1 The effect of cucurbitacin B on DSS-induced UC mice is shown, wherein: (A) The figure shows the weight change curve of each group of mice; (B) The figure shows the DAI change curve of each group of mice; (C) The figure shows the photos of the colon length change of each group of mice; (D) The figure shows the measured data of the colon length change of each group of mice. Compared with the control group, # P<0.05, ### P<0.001; *P<0.05 compared with the model group.

[0023] Depend on Figure 1 It can be seen that: Figure 1 Figure A shows that cucurbitacin B can significantly inhibit the weight loss of mice, especially the high-dose group (2 mg / kg) of cucurbitacin B; Figure 1 Figure B in the middle shows that cucurbitacin B significantly improved the DAI score; Figure 1As shown in Figures C and D, the colon length of mice in the DSS group was significantly shortened compared with the control group, and cucurbitacin B could significantly improve the colon length of mice treated with DSS. In summary, cucurbitacin B can significantly improve the symptoms of UC mice.

[0024] Example 2 In this example, cucurbitacin B was administered to DSS-induced UC mice, and the colon changes of UC mice were tracked and histological scores were evaluated. The steps were as follows: The treatment of mice was the same as that in "Experimental Example 1". After cervical dislocation, the colon tissues of all mice in the five groups were separated, measured and photographed as soon as possible. The colon contents were removed, fixed with 4% paraformaldehyde, embedded, sliced, stained and photographed under a microscope. Pathological changes such as edema, adhesion, ulceration and necrosis were observed, and histological scores were evaluated. The results are shown in Figure 2 , Figure 2 The effects of cucurbitacin B on DSS-induced colonic pathology in UC mice are shown, where: (A) The picture shows the HE staining of the colon of mice in each group; (B) The picture shows the pathological statistical results. Compared with the control group, ### P<0.001; compared with the model group, **P<0.01, ***P<0.001.

[0025] Depend on Figure 2 It can be seen that the colon damage of DSS-induced UC mice in the cucurbitacin B (1 and 2 mg / kg) groups was milder. It can be seen that cucurbitacin B administration can significantly alleviate the pathological changes of colon damage in DSS-induced UC mice and significantly improve the histopathological score of colon inflammation.

[0026] The raw materials and equipment used in the present invention, unless otherwise specified, are all commonly used raw materials and equipment in the art; the methods used in the present invention, unless otherwise specified, are all conventional methods in the art.

[0027] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any way. Any simple modification, change and equivalent transformation made to the above embodiment based on the technical essence of the present invention still falls within the protection scope of the technical solution of the present invention.

Claims

1. Application of cucurbitacin B in the preparation of a drug for preventing and / or treating inflammatory bowel disease.

2. The use according to claim 1, characterized in that: The dosage forms of the drug include granules, ordinary tablets, dispersible tablets, effervescent tablets, orally disintegrating tablets, lozenges, chewable tablets, capsules, soft capsules, microcapsules, pills, powders, drop pills, sustained-release preparations, controlled-release preparations, oral liquid preparations and injections.

3. Use of cucurbitacin B in the preparation of drugs for preventing and / or treating ulcerative colitis.

4. The use according to claim 3, characterized in that: The dosage forms of the drug include granules, ordinary tablets, dispersible tablets, effervescent tablets, orally disintegrating tablets, lozenges, chewable tablets, capsules, soft capsules, microcapsules, pills, powders, drop pills, sustained-release preparations, controlled-release preparations, oral liquid preparations and injections.

5. A composition for treating inflammatory bowel disease, characterized in that: The active ingredient of the composition is cucurbitacin B.

6. The composition according to claim 5, characterized in that: The inflammatory bowel disease is ulcerative colitis.

7. The composition according to claim 5, characterized in that: The composition includes one or more pharmaceutically acceptable excipients.

8. The composition according to claim 5, characterized in that: The composition is prepared into granules, ordinary tablets, dispersible tablets, effervescent tablets, orally disintegrating tablets, lozenges, chewable tablets, capsules, soft capsules, microcapsules, pills, powders, drop pills, sustained-release preparations, controlled-release preparations, oral liquid preparations and injections.